Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin for ICU yeast intra-abdominal infection
2024-516266-11-00Phase 3Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Aug 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Intra-abdominal candidiasis (IAC) and peritonitis comparing Caspofungin with Placebo (2 arms). Primary endpoint: 28-day failure rate after the beginning of treatment. Planned start Aug 2024; status: authorised.
02
Drugs
caspofungin
03
Conditions
Intra-abdominal candidiasis (IAC)peritonitis
Beyond the preview
Go deeper on 2024-516266-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516266-11-00.